Effects of Oral Chelation Drug Deferasirox in Iron Overload Conditions In Children

Objective: To know the efficacy and adverse events of oralchelation drug deferasirox in multitransfused patients with iron overload i.e beta thalassemia & dyserythropoietic anemia’s who are attending Rajiv Gandhi institute of medical sciences Srikakulam for trans fusions and management Material &methods; Prospective study conducted in dept. of pediatrics at RIMS Srikakulam from august 2014 to December 2016. 25 children are iron overload with multiple transfusions i.e. either betathalassemia major or dyserythropoietic anemia’s were taken for this study. All these were started oral iron chelation therapy i.e., Deferasirox . Results: In this study out of 25 children of iron overload 20 cases are thalassemia In these children 18 are on followup . out of them 1 male & 6 females children are below the age of 9 years. Remaining other are above 10 yrs. 5children presented with dyserythropoietic anemia. The adverse clinical effects are not that much for stoppage of the drug and resolved spontaneously with symptomatic support. Conclusion: The single daily dose oral chelation therapy Deferasirox is effective in beta-thalassemia and dyserythropoietic anemia with minimal adverse effects. Deferasirox appears as an effective oral iron chelator for longterm use.